Article Text

Download PDFPDF
Randomised controlled trial
Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome
  1. Peter P Toth
  1. Department of Preventive Cardiology, CGH Medical Center, Sterling, Illinois, USA
  1. Correspondence to : Dr Peter P Toth, Department of Preventive Cardiology, CGH Medical Center, 101 East Miller Rd, Sterling, IL 61081, USA; Peter.toth{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed


Use of statin therapy to treat dyslipidemia in patients with established coronary artery disease is the standard of care worldwide. Given the negative results of a number of trials that tested the use of adjuvant lipid-lowering therapies against a statin background, there has been great scepticism about whether or not non-statin drugs provide incremental benefit.1–3 Ezetimibe inhibits the absorption of both dietary and biliary cholesterol by inhibiting Niemann Pick C1 Like-1 protein.4 Ezetimibe has been the target of much criticism. Based on the ENHANCE trial,5 it appeared to lack efficacy …

View Full Text


  • Competing interests PPT is a consultant for Amgen, AstraZeneca, Kowa, Merck and Novartis. PPT is also involved in speaker's bureau activities for Amarin, AstraZeneca, Genzyme, GSK, Kowa and Merck.

  • Provenance and peer review Commissioned; internally peer reviewed.